Full name

A Phase 2b, Randomized, Controlled, Open-label Study to Evaluate the Immune Response and Safety of the RSVPreF3 OA Investigational Vaccine in Adults (>18 Years of Age) When Administered to Lung and Renal Transplant Recipients Comparing 1 Versus 2 Doses and Compared to Healthy Controls (>50 Years of Age) Receiving 1 Dose

NCT Number
NCT05921903
Geography
US
Non-US
Locations

Australia, Canada, Germany, Italy, Japan, Republic of Korea, Spain, United States

Primary Endpoints
  • RSV-A serum neutralizing titers expressed as mean geometric increase (MGI) post Dose 2 over post-Dose 1. At Visit 4 (Visit 3 + 30-42 days) versus Visit 3 (Day 30-60)
  • RSV-B serum neutralizing titers expressed as MGI post-Dose 2 over post-Dose 1. At Visit 4 (Visit 3 + 30-42 days) versus Visit 3 (Day 30-60)
External Link
https://clinicaltrials.gov/study/NCT05921903
Order
2
Disease
RSV
Menu title
A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above (RSV OA=ADJ-023)
Version
IDWEEK 2024
Phase
2